Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Adaptive Biotechnologies Corp (ADPT) AI Forecast

Our AI analyzed Adaptive Biotechnologies Corp. Create a free account to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$ADPT Neutral Signal Full forecast available
Sign Up Free

Adaptive Biotechnologies Corp (ADPT) Stock Forecast 2025

Adaptive Biotechnologies Corp (ADPT) AI Stock Price Forecast & Investment Analysis

Adaptive Biotechnologies Corp Stock Price Chart and Technical Analysis

Loading chart...

Adaptive Biotechnologies Corp (ADPT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Adaptive Biotechnologies Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 2, 2026, 10:50 p.m. (UTC)

Adaptive Biotechnologies Corp Investment Summary

When evaluating whether Adaptive Biotechnologies Corp (ADPT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Adaptive Biotechnologies Corp (ADPT) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $3 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Adaptive Biotechnologies Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Adaptive Biotechnologies Corp along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Adaptive Biotechnologies Corp is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Adaptive Biotechnologies Corp

Sign Up Free
Corporate Identity

Adaptive Biotechnologies Corp (Stock Symbol: ADPT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Adaptive Biotechnologies Corp's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Adaptive Biotechnologies Corp...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Adaptive Biotechnologies Corp...

Unlock Full Company Profile

Get complete details about Adaptive Biotechnologies Corp

Sign Up Free
Revenue & Growth Analysis

Adaptive Biotechnologies Corp generates annual revenues of $295 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Adaptive Biotechnologies Corp...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Adaptive Biotechnologies Corp...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Adaptive Biotechnologies Corp...

Unlock Financial Analysis

Get complete financial metrics for Adaptive Biotechnologies Corp

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Adaptive Biotechnologies Corp's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Adaptive Biotechnologies Corp strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Adaptive Biotechnologies Corp competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-30 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.58x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 3.35 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Adaptive Biotechnologies Corp (ADPT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Adaptive Biotechnologies Corp stock analysis.

Deep dive into Adaptive Biotechnologies Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Adaptive Biotechnologies Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Adaptive Biotechnologies Corp:

P/B Ratio 15.64x
Market Cap $3.38B
Book Value/Share $1.35
Revenue/Share $1.85
FCF/Share $-0.18
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Adaptive Biotechnologies Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Adaptive Biotechnologies Corp: An ROE of -63.0% indicates room for improvement in shareholder value creation.

ROE -63.0%
ROA -26.9%
ROIC -34.5%
Operating Margin -103.9%
Net Margin -97.8%
EBT Margin -103.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Adaptive Biotechnologies Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Adaptive Biotechnologies Corp: A current ratio of 3.35 indicates strong liquidity.

Current Ratio 3.35x
Quick Ratio 3.22x
D/E Ratio 1.30x
Financial Leverage 2.34x
Interest Coverage -6.7x
Working Capital $205M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Adaptive Biotechnologies Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Adaptive Biotechnologies Corp: Free cash flow of $-30M indicates cash challenges that need attention.

Operating Cash Flow $1.05B
Free Cash Flow -$30M
Capital Spending -$1.08B
FCF/Sales -10.0%
CapEx/Sales 365.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Adaptive Biotechnologies Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Adaptive Biotechnologies Corp: An asset turnover of 0.58x suggests room for improvement in asset utilization.

Asset Turnover 0.58x
Receivables Turnover 6.1x
Inventory Turnover 3.8x
Fixed Assets Turnover 9.6x
Days Sales Outstanding 60 days
Days Inventory 95 days
Payables Period 82 days
Cash Conversion Cycle 73 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Adaptive Biotechnologies Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Adaptive Biotechnologies Corp: With annual revenue of $295M, Adaptive Biotechnologies Corp demonstrates solid business size.

Income Statement
Total Revenue $295M
Operating Income -$144M
Net Income -$136M
R&D Expense $116M
SG&A Expense $173M
Cost of Goods Sold $43M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 292%
Cash & Short-term Investments 78%
Total Liabilities 282%
Short-term Debt 77%
Accounts Receivable 48%
Inventory 11%
Dividend & Shareholder Information
Shares Outstanding 160M
Growth Metrics (YoY)
Net Income Growth -97.8%

Latest Adaptive Biotechnologies Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Adaptive Biotechnologies Corp (ADPT) stock price and investment outlook.

source: WTOP News

SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Tuesday reported a loss of $20 million in its first quarter. The Seattle-based company said it had a loss of 13 cents per share.

source: CNN

View Adaptive Biotechnologies Corp. ADPT stock quote prices, financial information, real-time forecasts, and company news from CNN.

source: Nasdaq

In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $12.12, changing hands for $12.54/share. When a stock reaches ...

More news available

Sign up free to read all 8 news articles and stay updated on market developments.

Sign Up Free to Read More

Adaptive Biotechnologies Corp Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Adaptive Biotechnologies Corp against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $198M x 2.3x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $1M x x
Arcellx, Inc. ACLX ██% $6.73B x 16.7x
Alpha Cognition Inc. ACOG ██% $172M x 3.0x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.08B 12.6x 5.3x
Adaptive Biotechnologies Corp ADPT ██% $3.38B x 15.6x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $134M 2.1x x
Agentix Corp. AGTX ██% $800K x x
Aim Immunotech Inc. AIM ██% $8M x 3.7x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $229M x 22.0x
Aligos Therapeutics, Inc. ALGS ██% $35M x 1.1x
Allogene Therapeutics, Inc. ALLO ██% $718M x 2.6x
Alvotech ALVO ██% $1.13B x x
Amgen Inc AMGN ██% $201.93B 25.9x 22.0x
Apogee Therapeutics, Inc. APGE ██% $9.95B x x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $58.15B x x
Armata Pharmaceuticals, Inc. ARMP ██% $215M x x
Artiva Biotherapeutics, Inc. ARTV ██% $467M x 5.3x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $99M x x
Atyr Pharma Inc ATYR ██% $58M x 1.0x
Aura Biosciences, Inc. AURA ██% $801M x 7.5x
Autolus Therapeutics Plc AUTL ██% $421M x 3.9x
Anavex Life Sciences Corp. AVXL ██% $256M x 2.0x
Bioatla, Inc. BCAB ██% $7M x x
Biocardia, Inc. BCDA ██% $18M x x
Brainstorm Cell Therapeutics Inc. BCLI ██% $15M x x
Biocryst Pharmaceuticals Inc BCRX ██% $2.50B x x
Black Diamond Therapeutics, Inc. BDTX ██% $115M x 1.1x
Beam Therapeutics Inc. BEAM ██% $3.57B x 3.1x
Biogen Inc. BIIB ██% $31.81B 23.2x 1.7x
Biontech Se BNTX ██% $24.67B x x
Cabaletta Bio, Inc. CABA ██% $508M x 4.9x
Candel Therapeutics, Inc. CADL ██% $724M x 5.2x
C4 Therapeutics, Inc. CCCC ██% $452M x 1.9x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $5M x 0.8x
Cero Therapeutics Holdings, Inc. CERO ██% $530K x x
Cullinan Therapeutics, Inc. CGEM ██% $1.06B x 2.9x
Compugen Ltd CGEN ██% $201M 2.9x 2.0x
Cg Oncology, Inc. CGON ██% $6.24B x 5.7x
Cognition Therapeutics Inc CGTX ██% $101M x 3.4x
Coherus Oncology, Inc. CHRS ██% $222M 1.2x 2.8x
Calidi Biotherapeutics, Inc. CLDI ██% $3M x 0.6x
Cellectis S.A. CLLS ██% $296M x x
Compass Therapeutics, Inc. CMPX ██% $393M x 2.1x
Mosaic Immunoengineering Inc. CPMV ██% $5M x x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $88M x 2.5x
Cardiol Therapeutics Inc. CRDL ██% $121M x x
Curis Inc CRIS ██% $15M x 1.2x
Crispr Therapeutics Ag CRSP ██% $5.36B x 3.0x
Champions Oncology, Inc. CSBR ██% $84M x 19.6x
Cel Sci Corp CVM ██% $19M x 2.8x
Dbv Technologies S.A. DBVT ██% $922M x 5.5x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $634M x 1.4x
Denali Therapeutics Inc. DNLI ██% $4.04B x 4.4x
Precision Biosciences Inc DTIL ██% $203M x 2.7x
Dyadic International Inc DYAI ██% $37M x x
Editas Medicine, Inc. EDIT ██% $536M x 121.5x
Eloxx Pharmaceuticals, Inc. ELOX ██% $8M x x
Elutia Inc. ELUT ██% $41M 0.8x 1.8x
Engene Therapeutics Inc. ENGN ██% $118M x 0.5x
Entera Bio Ltd. ENTX ██% $79M x 7.4x
Viskase Holdings, Inc. ENZN ██% $31M x 0.2x
Estrella Immunopharma, Inc. ESLA ██% $41M x x
Evaxion A/S EVAX ██% $27M x x
Exelixis, Inc. EXEL ██% $13.69B 16.4x 7.1x
Exozymes Inc. EXOZ ██% $72M x 47.2x
Fate Therapeutics Inc FATE ██% $351M x 2.0x
4d Molecular Therapeutics, Inc. FDMT ██% $663M x 1.5x
Fennec Pharmaceuticals Inc. FENC ██% $366M x 9.7x
Finch Therapeutics Group, Inc. FNCH ██% $12M 0.5x 0.9x
Finch Therapeutics Group, Inc. FNCHQ ██% $12M 0.5x 0.8x
Futuretech Ii Acquisition Corp. FTII ██% $52M x x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $156.45B 17.0x 6.7x
Monte Rosa Therapeutics, Inc. GLUE ██% $2.03B x 3.9x
Genenta Science S.P.A. GNTA ██% $41M x 3.3x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $260K x x
Greenland Mines Ltd GRML ██% $36M x 0.7x
Halozyme Therapeutics, Inc. HALO ██% $9.31B 26.7x 42.4x
Humacyte, Inc. HUMA ██% $181M x 15.6x
Immunitybio, Inc. IBRX ██% $9.64B x x
Inhibikase Therapeutics, Inc. IKT ██% $256M x 1.5x
Imagenebio, Inc. IMA ██% $65M x 0.5x
Immunocore Holdings Plc IMCR ██% $1.65B x 4.2x
Immatics N.V. IMTX ██% $1.32B x x
Immunovant, Inc. IMVT ██% $7.78B x 9.1x
In8bio, Inc. INAB ██% $14M x 0.6x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $55M x x
Inmune Bio, Inc. INMB ██% $45M x 2.3x
Intensity Therapeutics, Inc. INTS ██% $11M x 1.1x
Iovance Biotherapeutics, Inc. IOVA ██% $1.74B x 2.4x
Century Therapeutics, Inc. IPSC ██% $430M x 1.6x
Invivyd, Inc. IVVD ██% $242M x 1.2x
Jasper Therapeutics, Inc. JSPR ██% $13M x 3.8x
Kalaris Therapeutics, Inc. KLRS ██% $104M x 1.5x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.31B x 20.7x
Krystal Biotech, Inc. KRYS ██% $10.94B 48.6x 8.6x
Kymera Therapeutics, Inc. KYMR ██% $9.29B x 6.0x
Kyverna Therapeutics, Inc. KYTX ██% $511M x 2.6x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $335M x 6.2x
Lenz Therapeutics, Inc. LENZ ██% $182M x 0.7x
Atyr Pharma Inc LIFE ██% $1.90B x 32.8x
Liminatus Pharma, Inc. LIMN ██% $6M x x
Leonabio, Inc. LONA ██% $79M x 1.6x
Lexeo Therapeutics, Inc. LXEO ██% $330M x 1.4x
Maze Therapeutics, Inc. MAZE ██% $1.65B x 4.8x
Mesoblast Ltd MESO ██% $1.82B x x
Meiragtx Holdings Plc MGTX ██% $1.19B x x
Metagenomi Therapeutics, Inc. MGX ██% $46M x 0.3x
Molecular Partners Ag MOLN ██% $159M x x
Moderna, Inc. MRNA ██% $28.78B x 3.9x
Neurocrine Biosciences Inc NBIX ██% $17.30B 25.9x 5.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $291M x 4.1x
Novavax Inc NVAX ██% $1.56B x x
Ocugen, Inc. OCGN ██% $501M x 86.3x
Outlook Therapeutics, Inc. OTLK ██% $178M x x
Palisade Bio, Inc. PALI ██% $330M x 2.6x
Passage Bio, Inc. PASG ██% $15M x 1.3x
Vaxcyte, Inc. PCVX ██% $8.09B x 2.7x
Biomx Inc. PHGE ██% $4M x x
Pluri Inc. PLUR ██% $22M x x
Protalix Biotherapeutics, Inc. PLX ██% $184M 12.0x 2.7x
Pharmacyte Biotech, Inc. PMCB ██% $8M x 0.2x
Prime Medicine, Inc. PRME ██% $703M x 9.2x
Prokidney Corp. PROK ██% $571M x x
Pelthos Therapeutics Inc. PTHS ██% $94M x 2.7x
Qiagen N.V. QGEN ██% $8.49B x 2.3x
Quince Therapeutics, Inc. QNCX ██% $16M 1.9x 1.0x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $928M x 5.6x
Repligen Corp RGEN ██% $7.84B 152.5x 3.7x
Regenxbio Inc. RGNX ██% $676M x 32.1x
Relay Therapeutics, Inc. RLAY ██% $3.87B x 6.0x
Revolution Medicines, Inc. RVMD ██% $37.54B x 25.0x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.95B x 1.9x
Sab Biotherapeutics, Inc. SABS ██% $297M x 1.3x
Sana Biotechnology, Inc. SANA ██% $961M x 8.1x
Scilex Holding Co SCLX ██% $55M x x
Scinai Immunotherapeutics Ltd. SCNI ██% $1M x 0.2x
Sangamo Therapeutics, Inc SGMO ██% $29M x x
Solid Biosciences Inc. SLDB ██% $1.02B x 2.7x
Silexion Therapeutics Corp SLXN ██% $3M x 9.4x
Senti Biosciences Holdings, Inc. SNTI ██% $33M x 12.9x
Scholar Rock Holding Corp SRRK ██% $6.29B x 22.8x
Surrozen, Inc./De SRZN ██% $299M x x
Sutro Biopharma, Inc. STRO ██% $501M x x
Protara Therapeutics, Inc. TARA ██% $222M x 1.2x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.82B x 8.1x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $69M x 0.7x
Bio-Techne Corp TECH ██% $11.10B 101.3x 5.3x
Tectonic Therapeutic, Inc. TECX ██% $641M x 2.8x
Instil Bio, Inc. TIL ██% $52M x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $170M x 1.6x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.85B x 8.7x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $24M x x
Twist Bioscience Corp TWST ██% $6.12B x 13.4x
Voyager Acquisition Corp./Cayman Islands VACH ██% $541M 80.4x x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $504M x x
Vericel Corp VCEL ██% $2.33B 108.6x 6.5x
Vir Biotechnology, Inc. VIR ██% $1.61B x 2.0x
Vivosim Labs, Inc. VIVS ██% $3M x 0.6x
Vor Biopharma Inc. VOR ██% $1.13B x x
Vaxart, Inc. VXRT ██% $148M 4.0x 1.6x
Voyager Therapeutics, Inc. VYGR ██% $230M x 1.3x
Windtree Therapeutics Inc /De/ WINT ██% $480K x x
X4 Pharmaceuticals, Inc XFOR ██% $398M x 2.4x
Zeo Scientifix, Inc. ZEOX ██% $15M x 20.8x
Zivo Bioscience, Inc. ZIVO ██% $19M x x
Zura Bio Ltd ZURA ██% $473M x 2.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Adaptive Biotechnologies Corp Stock Forecast

How accurate are Adaptive Biotechnologies Corp stock predictions?

Our AI model shows a 28% Spearman correlation coefficient for ADPT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Adaptive Biotechnologies Corp stock price forecasts?

Our analysis considers Adaptive Biotechnologies Corp's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Adaptive Biotechnologies Corp a good investment in 2025?

Based on our AI analysis, Adaptive Biotechnologies Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Adaptive Biotechnologies Corp forecasts updated?

Adaptive Biotechnologies Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Adaptive Biotechnologies Corp?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...